Optimi Health Corp. (OPTH)

Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression

Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression

Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research

Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial

Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial

Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development

Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development

Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development

Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia

Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia

Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia

Diamond Equity Research Initiates Coverage on Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN)

Optimi Health Advances Highest-Purity Natural Psilocybin Extract to Date

Optimi Health Announces Closing of Oversubscribed US$15 Million Public Offering

SRx Health Solutions and EMJX Invest in Recent IPO and Commercial-Stage Pharmaceutical Company of Psychedelics, Optimi Health Corp. (OPTH)

Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting

Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting

Optimi Health Files LIFE Offering Document in Connection with NASDAQ Listing

Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products